Horizon Technology Finance Corp. 10-Q Summary
Business Context and Reporting Period
Company: Horizon Technology Finance Corp. (HRZN)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2013
Business Model: Externally managed Business Development Company (BDC) and Regulated Investment Company (RIC). The company primarily makes secured loans to development-stage companies in technology, life science, healthcare information and services, and cleantech industries.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2013 | Q1 2012 |
|---|---|---|
| Total Assets | $260,135 | $239,658 |
| Total Liabilities | $115,375 | $94,686 |
| Net Assets | $144,760 | $144,972 |
| Net Asset Value (NAV) per Share | $15.12 | $15.15 |
| Total Investment Income | $7,368 | $6,625 |
| Total Expenses | $4,595 | $3,273 |
| Net Investment Income | $2,773 | $3,352 |
| Net Realized Loss on Investments | $(210) | $0 |
| Net Unrealized Appreciation | $420 | $(813) |
| Net Increase in Net Assets from Operations | $2,983 | $2,539 |
| Net Investment Income per Share | $0.29 | $0.44 |
| Dividends Declared per Share | $0.345 | $0.450 |
| Total Borrowings | $110,037 | $89,020 |
| Cash and Money Market Funds | $4,597 | $3,608 |
Material Changes vs. Prior Period
- Investment Income: Increased 11.2% to $7.4 million, driven by a larger average loan portfolio size. However, fee income decreased significantly as there were no prepayment fees in Q1 2013 compared to $0.7 million in Q1 2012.
- Expenses: Total expenses rose 40.4% to $4.6 million. Interest expense increased due to higher average debt outstanding and the addition of the Fortress Facility and Senior Notes. Management fees increased due to higher gross assets.
- Net Investment Income: Decreased 17.3% to $2.8 million, primarily due to the reduction in fee income and higher interest expenses.
- Portfolio Composition: The portfolio grew from $228.6 million to $247.8 million. New loan funding totaled $28.5 million, offset by $10.0 million in principal payments.
- Asset Quality: The weighted average credit rating of the loan portfolio improved slightly from 3.2 to 3.1. Investments rated "2" (increased risk) rose from 1.6% to 7.9% of the portfolio, while "1" rated (deteriorating) remained at 2.2%.
Outlook, Risks, and Management Commentary
- Liquidity: The company maintains $4.6 million in cash and money market funds. It has $73.0 million in unused borrowing capacity across its Wells Facility ($8.0 million) and Fortress Facility ($65.0 million).
- Dividends: The Board declared monthly dividends of $0.115 per share for June, July, and August 2013. The company utilizes an "opt-out" dividend reinvestment plan.
- Asset Coverage: As of March 31, 2013, asset coverage for borrowed amounts was 225%, exceeding the 200% requirement under the Investment Company Act of 1940.
- Risks: Key risks include interest rate volatility (floating rate debt vs. fixed rate assets), credit risk in development-stage companies, and the potential for portfolio companies to require additional capital. Three investments remain on non-accrual status with a fair value of approximately $5.3 million.
- Unusual Items: The company recognized a net realized loss of $0.2 million primarily from the disposal of warrants. Net unrealized appreciation of $0.4 million offset this loss.
Investor Verification Checklist
- Non-Accrual Status: Verify the specific portfolio companies on non-accrual status (ACT Biotech, Cereplast, Satcon Technology) and the likelihood of recovery.
- Yield Compression: Confirm the trend in dollar-weighted average annualized yield, which dropped from 15.4% in Q1 2012 to 12.8% in Q1 2013.
- Debt Maturities: Review the maturity schedule of the Senior Notes (2019) and Credit Facilities to assess refinancing risks.
- Dividend Coverage: Assess whether Net Investment Income ($2.8M) is sufficient to cover declared dividends ($3.3M) without eroding capital, noting the reliance on return of capital or retained earnings.
- Concentration Risk: Review the top five loans, which represented 21% of the total loan portfolio as of March 31, 2013.